Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

Epidemiology, Risk Factors, and Outcomes of Infections of Lower Limb MEGAprostheses

NCT07544212 · tracked via the Priya Life Science Italy tracker
Phase
Observational
Started
2025-12-10
Last updated
2026-06-12

Condition(s) studied

Lower Limb Megaprosthetis Infection

Study summary

Retrospective, multicenter, non-profit observational study. The study will include consecutive patients who underwent lower-limb megaprosthesis implantation at the participating Centers between January 1, 2020, and June 30, 2023.

Eligibility

Sex
ALL
Min age
14 Years
Max age
100 Years
Healthy volunteers
No
Inclusion Criteria: * Age ≥ 14 years * Implantation of a lower-limb megaprosthesis at one of the participating centers between January 1, 2020, and June 30, 2023 * At least 2 years of follow-up after megaprosthesis implantation * Signed informed consent Exclusion Criteria: * None

Primary outcome measure(s)

  • Percent of patients with and without a diagnosis of megaprosthesis infection — 24 months after prosthesis placement
    Distribution of the study variables in the two groups of patients with and without megaprosthesis infection

Trial sites (1)

FacilityCityRegionStatus
Irccs Azienda Ospedaliero-Universitaria Di Bologna Bologna BO Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07544212 on ClinicalTrials.gov ↗ ← All trials in Italy